If you think you’ve come into contact with the virus, or if you have symptoms, isolate yourself and check your temperature every morning and evening for at least 10 days. Keep track of the readings. A fever is the most common COVID-19 symptom, but it’s sometimes below 100 F. In a...
Numerous studies on vaccine efficacy found that vaccinated individuals had a significantly lower risk of disease progression (risk ratio 0.38) and COVID-19-related death (risk ratio 0.16) [36]. Ferritin was associated with severity and death due to COVID [37, 38]. It increases in several inf...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a variety of clinical symptoms ranging from no or mild to severe disease. Currently, there are multiple postulated mechanisms that may push a moderate to severe disease into a c
Early flu symptoms easily can be confused with a common cold, but while cold symptoms come on gradually — flu typically will affect you fast. Flu symptoms alone aren’t enough for a diagnosis, and they can overlap quite a bit with COVID-19 symptoms. The Food and Drug Administration earli...
65 million people worldwide are estimated to suffer from long-term symptoms after their SARS-CoV-2 infection (Long COVID). However, there is still little information about the early recovery among those who initially developed Long COVID, i.e. had symptoms 4–12 weeks after infection but no...
Community health workers (CHWs) had important roles mitigating the impact of the COVID-19 pandemic in vulnerable communities. We described how CHWs supported the dissemination of COVID-19 information and services during the early pandemic response. Onlin
Participants and procedures Previously healthy adults aged between 18 and 50 years were eligible for the trial if they had early symptomatic COVID-19 (i.e., reported symptoms for ≤ 4 days), oxygen saturation ≥ 96%, were unimpeded in activities of daily living, and gave fully ...
The antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals with COVID-19. Methods This randomised, plac...
We computed hesitancy by inverting the proportion of individuals “who either have already received a COVID vaccine or would definitely or probably choose to get vaccinated, if a vaccine were offered to them today.” See Supplementary Information for further details....
In randomized control trials, CP resulted in a 73% risk reduction of COVID-19 progression when given within 3 days of symptoms19, but has had a mixed mortality benefit in randomized clinical trials when given later in illness to severe COVID-19 patients21. Similar results were obtained with...